This points to a potential role for TFF1 in the vagina's innate immune defence and could be of clinical relevance particularly after menopause, e.g., for the treatment of bacterial vaginosis or vulvovaginal candidiasis, as here vaginal dysbiosis is often observed as a consequence of estrogen deficiency. Here, TFF1 is linked to vulvovaginal candidiasis.